
A review of randomized clinical trials, nonrandomized trials and case reports suggests that the inflammatory bowel disease risk from treatment with IL-17 inhibitors is low.
Ittai Dayan, M.D., M.P.H., co-founder and CEO of Rhino Health, is one of 12 winners in this year's Emerging Leaders in Healthcare feature. In this video interview, Dayan not only shares a good read for healthcare professionals, but also a turning point that changed his career trajectory and even a guilty pleasure of his — which involves finishing a scoop or more of his son's ice cream.
almost 3 years ago
Sickle Cell Disease Finally Getting its Duealmost 3 years ago
Ghost Network Bustersalmost 3 years ago
A Snack in Bed Could Cure the Woes of Working in Healthcarealmost 3 years ago
Emerging Leaders in Healthcare: Lindsay Zimmerman of Upfront Healthcarealmost 3 years ago
Emerging Leaders in Healthcare: Hannah Ratcliffe of Waymark





